Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

American Airlines

Under Armour

Of the undervalued stocks that Goldman Sachs recently thrust into the spotlight, these three are the most promising stocks to buy. Here's what you need to know about each.

3 Undervalued Stocks to Buy According to Goldman Sachs

Biogen

Biogen and Regeneron Pharmaceuticals are most likely among large-cap biotech companies to top Wall Street's third-quarter sales and earnings expectations, an analyst said Friday.

Here Are Two Biotech Stocks To Watch As Earnings Season Kicks Off

Carnival

Gilead Sciences

Altria

Gilead Sciences, Altria, Regeneron Pharmaceuticals and Carnival present buying opportunities

Stocks That Fell to 3-Year Lows in the Week of Sept. 27

Regeneron Priced Right For Long-Term Investors

Investors are beginning to doubt Regeneron Pharmaceuticals' research prowess, an analyst said Tuesday, noting Regeneron stock has slid 33% since March. Year-to-date, the stock has lost 21%.

Is Regeneron Stock A Dud? Analyst Doubts Biotech's Research Prowess

Sanofi

Regeneron (REGN) and Sanofi get positive CHMP recommendation for the label expansion of asthma drug Dupixent in an additional indication.

Regeneron/Sanofi Gets Positive CHMP Opinion for Dupixent

The markets ignored Regeneron's latest quarterly earnings beat and stronger outlook.

Why Regeneron Is Still A Deep Value Play

Canon

Annaly Capital

Biogen Inc. (BIIB), Regeneron Pharmaceuticals Inc. (REGN), Canon Inc. (CAJ) and Annaly Capital Management Inc. (NLY) have declined to their respective three-year lows.

Stocks That Fell to 3-Year Lows in the Week of Sept. 6

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Regeneron (REGN) Down 5.2% Since Last Earnings Report: Can It Rebound?

Regeneron (REGN) and partner Sanofi get a favorable ruling against Amgen in the ongoing litigation of Praluent.

Regeneron-Sanofi Get Favorable Ruling Against Amgen in Court

Amgen

A U.S. judge on Wednesday set aside a jury verdict that found Amgen Inc  patents on its cholesterol drug Repatha were valid, handing a victory to Regeneron Pharmaceuticals Inc  and Sanofi SA , which sells a rival drug.

U.S. judge rules for Regeneron, Sanofi in Amgen cholesterol drug patent fight

Align Technology

Iovance Biotherapeutics

Sarepta Therapeutics

The more disruptive the market is, the more we look for companies that are not affected by the daily sturm and drang of the news cycle because they have supply chain issues in China.

Top Baird Health Care and Biotech Picks Have Massive Upside Potential

Regeneron (REGN) receives FDA approval for a prefilled syringe of its ophthalmology drug, Eylea.

Regeneron Gets FDA Nod for Eylea Injection Prefilled Syringe

Is Regeneron Pharmaceuticals Holdings (REGN) a great pick from the value investor's perspective right now? Read on to know more.

Is Regeneron Pharmaceuticals (REGN) A Great Pick for Value Investors?

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has received ample support from multiple catalysts this week.

Regeneron's Drug To Treat Genetic Form Of Bad Cholesterol Aces Late-Stage Trial

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) shares were trading higher Tuesday after Eylea, its product to treat retinal conditions, snagged another approval.

Regeneron's Eylea Prefilled Syringe Clears FDA Hurdle

Regeneron's (REGN) study on four investigational therapies for Ebola virus infection is stopped early as its therapy, REGN-EB3, was superior to Mapp Biopharmaceutical Inc.'s ZMapp in preventing death.

Regeneron Ebola Treatment Shows Promise, Study Stopped Early

Revenue and earnings beat Wall Street estimates thanks to solid growth for Eylea and Dupixent.

Regeneron Pharmaceuticals Reports Marked Improvement in Q2

Regeneron Pharmaceuticals, Inc. (REGN) CEO Leonard Schleifer on Q2 2019 Results - Earnings Call Transcript

Regeneron (REGN) tops on Q2 earnings and sales in the second quarter on the back of solid demand for ophthalmology drug, Eylea, and asthma drug, Dupixent.

Regeneron (REGN) Q2 Earnings Top Estimates, Eylea Sales Solid

Shares of Regeneron Pharmaceuticals Inc. REGN, -1.86% rose 2.2% in premarket trade Tuesday after the company reported second-quarter earnings that beat analysts' expectations.

Regeneron stock up 2.2% after earnings beat

Regeneron Pharmaceuticals (NASDAQ: REGN) reported second-quarter earnings of $6.04 per share, which beat the analyst consensus estimate of $5.37 by 12.48%.

Regeneron Pharmaceuticals Reports Q2 Earnings Beat

Regeneron Pharmaceuticals on Tuesday reported adjusted earnings of $6.02 per share on $1.93 billion in sales for its second quarter. In the year-earlier period, Regeneron earnings were $5.45 per share.

Regeneron Earnings Easily Beat Views

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports second-quarter 2019 results.

Is a Beat in the Cards for Regeneron (REGN) Q2 Earnings?

CRISPR Therapeutics

Editas Medicine

Intellia Therapeutics

Vertex Pharmaceuticals

The CRISPR pioneer is taking a slow-and-steady approach to drug development. If peers are overlooking one key element of gene editing, that approach could pay off.

News for Regeneron Pharmaceuticals Stock (REGN)